miRTarBase

The experimentally validated microRNA-target interactions database

Features

1. Article Curation Growth
  • miRTarBase has curated 13,690 articles, expected to reach about 15,000 in the future.
2. NLP Enhancement with LLAMA3
  • Integration of the LLAMA3 model enhances accuracy and reduces false positives in detecting miRNA-target and disease associations.
3. miRNAs in drug resistance and therapeutic strategies
  • Contributed over 4,990 new interactions which highlight the role of miRNAs in drug resistance and therapeutic strategies.
  • Example: hsa-mir-122-5p interacting with the drug Sorafenib. The interaction leads to sensitivity, detected at a low level, particularly in relation to Hepatocellular Carcinoma. This effect was observed in multiple cell lines, including HepG2, Hep3B, and SK-Hep-1.[hsa-miR-122-5p]
4. Biomarker Identification
  • Identifying miRNAs as crucial biomarkers for toxicity assessment, treatment guidance, and optimization of therapeutic outcomes for individual patients.
  • Example: hsa-miR-122-5p is Predictive Biomarker (PRD) and Safety Biomarker (SAF) and exoression level is increased in Plasma, tested by microarrays, RT-PCR analysis. [miR-122]
5. miRNA Oxidation Modification
  • Information on oxidized miRNA sequences has been added, shedding light on how oxidative modifications influence miRNA targeting and regulation.
  • Example: G > T at position 4 (4G > T) of let-7a. 4o8G-let-7 (anti-4oxo) were prepared to harbour a tandem repeat of cognate target sites, and their specific inhibition was validated by luciferase reporter assays. [hsa-let-7a-5p]
6. High-throughput Validation Expansion
  • Increased validation of MTIs through high-throughput methods like CLIP-seq and PAR-CLIP.
7. System Overhaul
  • Comprehensive data reorganization, corrections, and a revamp of website and backend for improved usability.